{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06161415",
            "orgStudyIdInfo": {
                "id": "71341"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study",
            "officialTitle": "Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops , an Innovative ImmunomodulatOr Targeting Aryl hydrocarboN Receptor (AhR): The LION Study",
            "acronym": "LION",
            "therapeuticArea": [
                "Other"
            ],
            "study": "safety-tolerability-and-distribution-of-laquinimod-eye-drops-the-lion-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-29",
            "studyFirstSubmitQcDate": "2023-11-29",
            "studyFirstPostDateStruct": {
                "date": "2023-12-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Quan Dong Nguyen",
                "investigatorTitle": "Professor of Ophthalmology",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Quan Dong Nguyen",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Global Ophthalmic Research Center (GORC)",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.",
            "detailedDescription": "Participants who fulfill the study eligibility criteria and who are planned to undergo a pars plana vitrectomy will be enrolled in the study. Eligible participants scheduled for a diagnostic vitrectomy may also be enrolled.\n\nThe study will consist of two stages:\n\nStage One - Open label dose escalation:\n\nUp to three subsequent dose-escalation groups will receive Laquinimod eye drops for 2 weeks and samples will be assayed for Laquinimod concentration in aqueous humor, vitreous and plasma.\n\nStage Two- Randomized, Controlled Comparison of 2 Laquinimod doses:\n\nAfter the dose escalation cohorts are analysed, 2 Laquinimod doses will be selected for a randomized comparison. The doses in stage 2 will not exceed those studied in stage 1."
        },
        "conditionsModule": {
            "conditions": [
                "Inflammation",
                "Uveitis"
            ],
            "keywords": [
                "Uveitis",
                "Inflammation",
                "Laquinimod eye drops",
                "Topical",
                "Immunomodulation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The study will consist of two stages:\n\nStage One - Open label dose escalation:\n\nUp to three subsequent dose-escalation groups will receive Laquinimod eye drops for 2 weeks and samples will be assayed for Laquinimod concentration in aqueous humor, vitreous and plasma.\n\nStage Two- Randomized, Controlled Comparison of 2 Laquinimod doses:\n\nAfter the dose escalation cohorts are analysed, 2 Laquinimod doses will be selected for a randomized comparison. The doses in stage 2 will not exceed those studied in stage 1.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1",
                    "type": "EXPERIMENTAL",
                    "description": "(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops once a day (0.6mg per day) in the study eye for 14 days before the surgery.",
                    "interventionNames": [
                        "Drug: Laquinimod eye drops"
                    ]
                },
                {
                    "label": "Group 2",
                    "type": "EXPERIMENTAL",
                    "description": "(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops twice a day (1.2mg per day) in the study eye for 14 days before the surgery",
                    "interventionNames": [
                        "Drug: Laquinimod eye drops"
                    ]
                },
                {
                    "label": "Group 3",
                    "type": "EXPERIMENTAL",
                    "description": "(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops three times a day(1.8 mg per day) for 14 days before the surgery.",
                    "interventionNames": [
                        "Drug: Laquinimod eye drops"
                    ]
                },
                {
                    "label": "Stage 2 Comparison Group A",
                    "type": "EXPERIMENTAL",
                    "description": "(3 to 6 participants): Participants will receive a dose of Laquinimod eye drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.",
                    "interventionNames": [
                        "Drug: Laquinimod eye drops"
                    ]
                },
                {
                    "label": "Stage 2 Comparison Group B",
                    "type": "EXPERIMENTAL",
                    "description": "(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.",
                    "interventionNames": [
                        "Drug: Laquinimod eye drops"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Laquinimod eye drops",
                    "description": "n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned",
                    "armGroupLabels": [
                        "Group 1",
                        "Group 2",
                        "Group 3",
                        "Stage 2 Comparison Group A",
                        "Stage 2 Comparison Group B"
                    ],
                    "otherNames": [
                        "LAQ eye drops"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Concentration of Laquinimod in aqueous humor and vitreous samples of human participants",
                    "description": "Assessment of concentration of Laquinimod in aqueous humor and vitreous samples of human by biolanalysis in specialized lab participants on Day 14 of Laquinimod eye-drop administration.",
                    "timeFrame": "After 2 weeks of study drug administration"
                },
                {
                    "measure": "Concentration of Laquinimod in plasma of human participants",
                    "description": "Assessment of concentration of Laquinimod in plasma of human participants on Day 14 of Laquinimod in specialized lab eye-drop administration. participants on Day 14 of Laquinimod eye-drop administration.",
                    "timeFrame": "After 2 weeks of study drug administration"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety Assessment",
                    "description": "Any Adverse events: ocular and non-ocular at Post operative Day 1 and Post operative Day 8 compared to baseline.",
                    "timeFrame": "Baseline to end of Study at 22-30days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 years or older\n2. Participants who are capable and willing to provide informed consent and follow study instructions.\n3. Participants who are scheduled to undergo pars plana vitrectomy (PPV).\n4. Participants with intraocular pressure (IOP) \u2265 5 mmHg and \u226422 mmHg in study eye\n5. Women who are not pregnant or lactating, are post-menopausal or have undergone a sterilization procedure.\n\nExclusion Criteria:\n\n1. Participants with active periocular or ocular infectious disease (e.g., blepharitis, scleritis, or conjunctivitis, keratitis or endophthalmitis).\n2. Participants with active infectious uveitis\n3. Participants with a history of prior intraocular or extraocular surgery within 90 days of study enrollment\n4. Participant with a history of intravitreal steroids administered to the study eye within 90 days of enrollment.\n5. Participants with a history of intravitreal injection of VEGF inhibitors within 30 days of enrollment\n6. Use of any topical cyclosporine or corticosteroid or other specified (i.e. calcineurin inhibitors) ophthalmic medication in the study eye for any reason within 14 days of enrollment and before the surgery\n7. Use of medication consisting of a strong or moderate inhibitor of CYP3A4 within 2 weeks of Baseline visit (and during the study).\n8. Use of medication consisting of a strong inducer of CYP3A4 within 2 weeks of Baseline visit (and during the study)\n9. Mild, moderate, or severe hepatic impairment (any of Child-Pugh Score A, B, and C)\n10. Moderate or severe renal impairment (GFR \u226460 mL/min)\n11. History of HIV disease or other immunodeficiency disorder\n12. History of acute hepatitis A (IgM positive), hepatitis B, or hepatitis C\n13. History of organ or bone marrow transplant\n14. Presence of malignancy under active treatment\n15. Any other acute or chronic medical condition that would, in the judgment of the study investigators, reasonably preclude participation in the clinical study\n16. Already enrolled in a clinical trial.\n17. Any condition that would prevent the investigator from acquiring images of the eye as required per protocol",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Spencer Center for Vision Research at the Byers Eye Institute",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94303",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "LION Study Team",
                            "role": "CONTACT",
                            "phone": "650-723-6995",
                            "email": "nguyenlabtrials@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014605",
                    "term": "Uveitis"
                },
                {
                    "id": "D000007249",
                    "term": "Inflammation"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000014603",
                    "term": "Uveal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "asFound": "Inflammation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17353",
                    "name": "Uveitis",
                    "asFound": "Uveitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17351",
                    "name": "Uveal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5824",
                    "name": "Uveal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009883",
                    "term": "Ophthalmic Solutions"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "asFound": "Cerebral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3628",
                    "name": "Adjuvants, Immunologic",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}